Related Experiment Video
Updated: Jan 19, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols
Jay J H Park1,2, Ellie Siden2, Michael J Zoratti3
1Experimental Medicine, Department of Medicine, 10th Floor, 2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
Background:
Master protocols, classified as basket trials, umbrella trials, and platform trials, are novel designs that investigate multiple hypotheses through concurrent sub-studies (e.g., multiple treatments or populations or that allow adding/removing arms during the trial), offering enhanced efficiency and a more ethical approach to trial evaluation. Despite the many advantages of these designs, they are infrequently used.
Methods:
We conducted a landscape analysis of master protocols using a systematic literature search to determine what trials have been conducted and proposed for an overall goal of improving the literacy in this emerging concept. On July 8, 2019, English-language studies were identified from MEDLINE, EMBASE, and CENTRAL databases and hand searches of published reviews and registries.
Results:
We identified 83 master protocols (49 basket, 18 umbrella, and 16 platform trials). The number of master protocols has increased rapidly over the last five years. Most have been conducted in the US (n = 44/83) and investigated experimental drugs (n = 82/83) in the field of oncology (n = 76/83). The majority of basket trials were exploratory (i.e., phase I/II; n = 47/49) and not randomized (n = 44/49), and more than half (n = 28/48) investigated only a single intervention. The median sample size of basket trials was 205 participants (interquartile range, Q3-Q1 [IQR]: 500-90 = 410), and the median study duration was 22.3 (IQR: 74.1-42.9 = 31.1) months. Similar to basket trials, most umbrella trials were exploratory (n = 16/18), but the use of randomization was more common (n = 8/18). The median sample size of umbrella trials was 346 participants (IQR: 565-252 = 313), and the median study duration was 60.9 (IQR: 81.3-46.9 = 34.4) months. The median number of interventions investigated in umbrella trials was 5 (IQR: 6-4 = 2). The majority of platform trials were randomized (n = 15/16), and phase III investigation (n = 7/15; one did not report information on phase) was more common in platform trials with four of them using seamless II/III design. The median sample size was 892 (IQR: 1835-255 = 1580), and the median study duration was 58.9 (IQR: 101.3-36.9 = 64.4) months.
Conclusions:
We anticipate that the number of master protocols will continue to increase at a rapid pace over the upcoming decades. More efforts to improve awareness and training are needed to apply these innovative trial design methods to fields outside of oncology.
Insights
Master protocols, including basket, umbrella, and platform trials, are efficient and ethical clinical trial designs. Their use is rapidly increasing, particularly in oncology, with more awareness and training needed for broader application.
Area of Science:
- Clinical trial design
- Biostatistics
- Translational research
Background:
- Master protocols (basket, umbrella, platform trials) offer efficient, ethical, multi-hypothesis clinical trial evaluation.
- Despite advantages, these innovative designs are underutilized in clinical research.
Purpose of the Study:
- To conduct a landscape analysis of master protocols to improve understanding of their current use.
- To identify trends and characteristics of implemented master protocols.
Main Methods:
- Systematic literature search of MEDLINE, EMBASE, and CENTRAL databases, including hand searches.
- Data collected on master protocols identified up to July 8, 2019.
- Analysis focused on trial design, interventions, populations, and outcomes.
Main Results:
- Identified 83 master protocols (49 basket, 18 umbrella, 16 platform), with rapid recent growth.
- Most trials were in oncology, investigating experimental drugs, primarily in the US.
- Basket and umbrella trials were mostly exploratory and non-randomized; platform trials were predominantly randomized and phase III.
Conclusions:
- Master protocol utilization is projected to increase significantly in the coming decades.
- Increased awareness and training are crucial to expand the application of these designs beyond oncology.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Bioequivalence studies: Biowaivers
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioavailability Study Design: Healthy Subjects Versus Patients

